WO2005114322A2 - Manufacturing process, such as three-dimensional printing, including solvent vapor filming and the like - Google Patents
Manufacturing process, such as three-dimensional printing, including solvent vapor filming and the like Download PDFInfo
- Publication number
- WO2005114322A2 WO2005114322A2 PCT/US2005/016698 US2005016698W WO2005114322A2 WO 2005114322 A2 WO2005114322 A2 WO 2005114322A2 US 2005016698 W US2005016698 W US 2005016698W WO 2005114322 A2 WO2005114322 A2 WO 2005114322A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- water
- solvent
- soluble
- particles
- organic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y10/00—Processes of additive manufacturing
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y70/00—Materials specially adapted for additive manufacturing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30003—Material related properties of the prosthesis or of a coating on the prosthesis
- A61F2002/3006—Properties of materials and coating materials
- A61F2002/30062—(bio)absorbable, biodegradable, bioerodable, (bio)resorbable, resorptive
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30108—Shapes
- A61F2002/30199—Three-dimensional shapes
- A61F2002/30224—Three-dimensional shapes cylindrical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30108—Shapes
- A61F2002/30199—Three-dimensional shapes
- A61F2002/30224—Three-dimensional shapes cylindrical
- A61F2002/30225—Flat cylinders, i.e. discs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/30767—Special external or bone-contacting surface, e.g. coating for improving bone ingrowth
- A61F2/30771—Special external or bone-contacting surface, e.g. coating for improving bone ingrowth applied in original prostheses, e.g. holes or grooves
- A61F2002/30772—Apertures or holes, e.g. of circular cross section
- A61F2002/30784—Plurality of holes
- A61F2002/30785—Plurality of holes parallel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/3094—Designing or manufacturing processes
- A61F2002/30985—Designing or manufacturing processes using three dimensional printing [3DP]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0004—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0063—Three-dimensional shapes
- A61F2230/0069—Three-dimensional shapes cylindrical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00005—The prosthesis being constructed from a particular material
- A61F2310/00179—Ceramics or ceramic-like structures
- A61F2310/00293—Ceramics or ceramic-like structures containing a phosphorus-containing compound, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00005—The prosthesis being constructed from a particular material
- A61F2310/00353—Bone cement, e.g. polymethylmethacrylate or PMMA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/432—Inhibitors, antagonists
- A61L2300/434—Inhibitors, antagonists of enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y80/00—Products made by additive manufacturing
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/15—Sheet, web, or layer weakened to permit separation through thickness
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/24—Structurally defined web or sheet [e.g., overall dimension, etc.]
- Y10T428/24273—Structurally defined web or sheet [e.g., overall dimension, etc.] including aperture
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/31504—Composite [nonstructural laminate]
Definitions
- Fig. 1 is a digital image showing a heavily bled three dimensional printing structure on the left and a lightly bled structure on the right;
- FIG. 2A is a digital image of a scanning electromicrograph of an article made by a vapor film forming method of an invention hereof having a powder mixture of 80% sugar and 20% PCL at a magnification of X50.
- Fig. 2B is a digital image of the article shown in Fig. 2A, at a magnification of X160.
- Fig. 2C is a digital image of the article shown in Fig. 2A, at a magnification of X900.
- FIG. 3A is a digital image of a scanning electromicrograph of an article made by a vapor film forming method of an invention hereof having a powder mixture of 70% sugar and 30% PCL at a magnification of X55.
- Fig. 3B is a digital image of the article shown in Fig. 3A, at a magnification of X250.
- Fig. 4A is a digital image of a scanning electromicrograph of an article made by a prior art method printing liquid chloroform and a powder mixture of 80% NaCl and 20% PCL at a magnification of X150.
- Fig. 4B is a digital image of the prior art article shown in Fig. 4A, at a magnification of X250.
- Fig. 4C is a digital image of the prior art article shown in Fig. 4A, at a magnification of X650.
- FIG. 5 in eight subparts are schematic renditions of geometries that can be made according to methods of inventions disclosed herein, with:
- FIG. 5A representing a first waffle pattern, with .6mm pores and .6mm posts .
- Fig. 5B representing a second waffle pattern, with .6mm pores and .6mm posts.
- Fig. 5C representing a first waffle pattern, with .5mm pores and .5mm posts.
- Fig. 5D representing an assembly with three first waffle pattern elements, with 1mm posts and two second waffle pattern elements with .5mm posts.
- Fig. 5E representing a second waffle pattern, with lmm pores and .5mm posts.
- Fig. 5F representing a second waffle pattern, with .75mm pores and posts (50%) .
- Fig. 5G representing a first waffle pattern, with lmm pores and .5mm posts;
- FIG. 5H representing a second waffle pattern, with .5mm pores and .5mm posts.
- Schematic flow chart showing steps of a 3D Printing vapor filming embodiment of a method of an invention hereof.
- FIG. 7 is a schematic rendition of a cross-section of a preform for use with method inventions hereof, having a first type of particulate material that is adhered to other particles of the same type, shown unshaded, to which are also stuck a second type of particles (shaded) .
- Fig. 8 is a schematic rendition of a cross-section of the preform shown in Fig. F, where the second type of bound structure particulate material has been filmed and flowed to follow closely the contours of the adhered structure of the first particulate material.
- Fig. 9 is a schematic rendition of a cross-section of a preform such as shown in Fig. 8, in which the first type of particulate material has been removed, such as by a solvent, and the second type of material forming films remains.
- Fig. 10 is a digital image of two similar parts, the part on the left having been made by conventional dispensing of liquid chloroform, the part on the right having been made by a process of an invention hereof.
- FIG. 11 is digital image of the same features printed by two different methods, showing printing with liquid chloroform on the left and printing with liquid water followed by solvent vapor filming fusing of an invention hereof, on the right .
- Fig. 12 is a digital image of the same features of similar parts showing printing water only on the right, and printing a sucrose solution on the left, both into powder that contains sucrose. Neither has been vapor filmed.
- Fig. 13A is a digital image of part made by printing an aqueous binder (pure water) into a powder bed composed of polycaprolactone (PCL) 20%, tricalcium phosphate (TCP) 20% and sugar 60%; tf l J l & , &i*& digital image of the part shown in Fig . 13A at a higher magni fication .
- PCL polycaprolactone
- TCP tricalcium phosphate
- Fig. 13C is a digital image of an electromicrograph of the part shown in Fig. 13A, at a magnification of x55;
- Fig. 13D is a digital image of an electromicrograph of the part shown in Fig. 13A, at a magnification of x400.
- Fig. 13E is a digital image of an electromicrograph of the part shown in Fig. 13A, at a magnification of x750.
- Fig. 14 is a schematic flow chart showing a method of an invention hereof using a preform that is created by a method other than three dimensional printing.
- Fig. 15 is a digital image showing large scale features and small scale porosity.
- Three-dimensional printing (3DP) described in U.S. patent 5,204,055 (incorporated herein by reference), has proven to be useful in creating structures for a variety of purposes including medical applications such as bone substitutes and tissue scaffolds.
- a layer of powder has been deposited such as by roller spreading, and then drops of a binder liquid have been dispensed onto the powder layer by techniques related to ink-jet printing.
- the dispensers have been moved by motion control apparatus and have included raster printing or vector printing, or both, in various combinations. Powder particles have been joined together by the action of the binder liquid. Subsequent powder layers have been sequentially deposited and drops of binder liquid dispensed until the desired three-dimensional object is created. Unbound powder has supported printed regions until the drying of the article and then unbound powder has been removed to leave a printed article or preform.
- bS ⁇ i l" "'" l Sin n'g li;: o l F " ffie particles has been achieved through any one or more of several mechanisms.
- One mechanism has been that the binder liquid has sometimes dissolved some of the powder. Then, as the solvent in the binder liquid has evaporated, the material from partially or fully dissolved particles has resolidified so as to form a joined or solid mass of that material.
- Another mechanism has been that the binder liquid has contained a dissolved binding substance which has been left behind when the volatile part of the binder liquid evaporates, and upon evaporation of the volatile, the dissolved binder substance has solidified around solid particles or solidified such that it is connected to solid particles, thereby binding solid particles together. It has also been possible for both of these effects to occur simultaneously.
- dissolution time scale during which the dissolution of powder particles into the dispensed binder liquid solvent occurs, as governed by the physical properties of the solvent and the solute.
- the molecular weight of a polymer can have a strong influence on d'.bsoluV-o* 1 ⁇ l : ,l ⁇ re is also an evaporation time scale which describes the evaporation of the dispensed binder liquid, or at least the solvent portion of the dispensed binder liquid, at typical three-dimensional printing conditions such as at room temperature.
- the evaporation time scale is essentially also the time scale for resolidification to occur.
- the dissolution time scale is a ratio which describes how much of the available inter- particle empty space is actually occupied by binder liquid.
- 3DP tends to require adjustment of printing parameters to values which are unique to a particular powder and a particular solvent or B'ihder ' Tqu'id'' e rg' use'd. if there are many powders or solvents/binders of interest, then significant effort can be required to determine specific printing parameters, i.e. it can be hard to respond quickly to a change in the formulation.
- Porous biostructures made of polymer are disclosed in U.S. patent 6,454,811, which is incorporated herein by reference. However, those structures were made by dispensing liquid chloroform from a printhead, which resulted in problems of bleeding of dispensed liquid in the powder bed, and so those articles did not have the dimensional resolution of the articles of the current invention.
- the dispensing of the liquid chloroform included using masks with a continuous stream of liquid chloroform, and the dispensing was performed onto a bed containing particles of PLGA and a leachable porogen.
- Solvent vapor fusing has also been used in other applications such as preparation of dental preforms using the vapor of liquid methyl methacrylate monomer in conjunction with acrylic cements, as described in U.S. patent 5,336,700.
- W 'Wi's "'1 ' ha* ' ⁇ W' ⁇ x tended to three-dimensional printing, nor has it involved leaching of a porogen for creation and control of pores.
- U.S. patent 5,171,834 discloses molding a part and then exposing it to solvent vapors.
- porous article made at least partly of polymer, which may include internal features, which is capable of undergoing significant elastic deformation without breaking.
- Such squeezability might make surgical installation easier, reduce the need for on-the-spot shaping during surgery, maintain contact pressure against neighboring tissue to promote tissue integration and ingrowth, etc.
- inventions disclosed herein include methods of manufacturing an article using three-dimensional printing for a portion of the manufacturing.
- the methods include three- dimensionally printing onto a powder bed which contains both orga ⁇ i Hstflv n ⁇ Mubl'e particles and organic-solvent-insoluble particles.
- the organic-solvent-insoluble particles may include water-soluble particles which may be selected for properties such as particle size and may include more than one substance.
- the organic-solvent-insoluble particles may further comprise at least one substantially insoluble substance such as a member of the calcium phosphate family. Printing may be done using an aqueous binder liquid.
- the preform may be exposed to the vapor of an organic solvent which causes the particles of organic-soluble-polymer to fuse to each other. This may further be followed by dissolving out the water-soluble particles, if such particles were present in the powder. Solvent vapor fusing together with the use of porogen particles may also be used in manufacturing methods other than 3DP.
- inventions also disclosed herein include articles which may be produced by the described methods .
- the articles can be characterized by a high porosity and by an ability to undergo large deformations without breaking, and by at least partial springback from such deformation, at least when made of appropriate polymer.
- the springback may be substantially instantaneous or may be time- dependent involving a time period of at least several seconds.
- an article of an invention hereof comprises a network or porous structure comprising an organic-solvent-soluble substance (s) which may be a polymer.
- s organic-solvent-soluble substance
- the article may be characterized by a geometry or morphology as having a basic structure, in which substantially all of the polymer has the form of a film which is somewhat randomly crinkled and perforated but is otherwise continuous. This is illustrated in Figs. 2A, 2B and 2C, representing magnifications of X50, X160 and X900, respectively. In this geometry or morphology, there is substantially no presence of identifiable polymer particles.
- An article of an invention disclosed herein can be characterized by a high porosity such as greater than 80% in regions which do contain the network (i.e., are not macroscopic polymer-free features) .
- a high porosity such as greater than 80% in regions which do contain the network (i.e., are not macroscopic polymer-free features) .
- an article of an invention disclosed herein can have macrochannels and other polymer-free macroscopic internal features with cross-sectional dimensions as small as approximately 100 micrometers, or larger cross-sectional dimensions. Examples of articles according to a present invention are shown in Figs. 5A-5H, which are, respectively, as identified above.
- the organic-solvent-soluble network in an article can comprise a polymer such as polycaprolactone, and can comprise a comb polymer. Polymethylmethacrylate and the PLGA family are also polymers which could be used.
- the organic-solvent-soluble substance in the article can be biologically resorbable if desired.
- the organic-solvent-soluble substance can be the same everywhere in the biostructure or it can be different at different places in the biostructure.
- the article can also comprise an insoluble (i.e., insoluble in substantially any solvent) material, which may exist in the form of particles of the insoluble material which are at least partly held by the polymeric structure.
- the organic-solvent-insoluble substance which is present in the finished article can be a member of the calcium phosphate family, so as to be useful for bone growth applications.
- the insoluble substance can be tricalcium phosphate, which is resorbable.
- Composition of the insoluble material (s) also can vary from place to place within the article.
- an article of an invention disclosed herein can have mechanical properties such that the article can undergo a large deformation and display at least some resilience (springback) .
- an article of a disclosed invention when made from polycaprolactone, can be elastically deformed to strains of at least 10% and can then spring at least partway back to its original shape and dimensions.
- the springback may be substantially instantaneous or may be time-dependent involving a time period of at least several seconds.
- the polymer network in the finished article has a geometry which is tortuous and comprises crinkled perforated films. This, together with the material properties of polymers such as polycaprolactone is believed to be related to the ability of the article to elastically deform to rather large strains. The possible time-dependent springback is believed to be due to similar factors.
- inventions disclosed herein include methods of manufacturing which include solvent vapor fusing and may include using three-dimensional printing for a portion of the manufacturing process .
- the manufacturing process starting with three-dimensional printing is illustrated in the Fig. 6.
- the method of manufacturing a biostructure may include the following steps as illustrated in Fig. 6.
- a layer of powder may be deposited 602, such as by roller spreading or other suitable means.
- This powder may comprise particles of at least two substances.
- the powder may comprise particles of at least one substance, designated an organic-solvent-soluble substance, which is soluble in an organic solvent of interest but which has a low or negligible solubility in water. Additionally, the powder may comprise particles of an organic-solvent-insoluble substance.
- Choices regarding the organic-solvent-insoluble substance (s) which may comprise water-soluble substances or substances which are ⁇ sseritl 'iy""ins ⁇ " 'ftl'e :;i " ⁇ l l any solvent, or both types of substances, are described elsewhere herein.
- Organic-solvent-soluble substances of interest include essentially any polymer which may be of interest for biological applications and which is soluble in a suitable organic solvent.
- Specific polymers of interest include polycaprolactone and comb polymers, and polymethylmethacrylate and members of the poly lactic co-glycolic acid (PLGA) family.
- Polycaprolactone (Sigma-Aldrich, St. Louis, MO) may, for example, have a molecular weight of approximately 60,000 to 65,000 Daltons.
- What is referred to here as an organic- solvent-soluble substance could be a mixture of more than one organic-solvent-soluble substances, either existing as discrete particles blended among each other or commingled within individual particles.
- the organic-solvent-soluble substance can be the same everywhere in the biostructure or it can be different at different places in the biostructure. This can be accomplished, for example, by spreading different powders in different layers of the three-dimensional printing process.
- organic-solvent-soluble and organic-solvent-insoluble reference may be made to an organic solvent of interest for a particular substance or application.
- An organic solvent of particular interest is chloroform (CHC1 3 ), because of the large number of substances which chloroform is capable of dissolving.
- Other chlorinated hydrocarbons are similarly of interest, as are still other organic solvents.
- supercritical carbon dioxide can be considered as a solvent capable of causing the particles of polymer (organic-solvent-soluble substance) to solvent-fuse.
- the proportions of the various components of the powder may be chosen with a view toward how they will form structures, such as which types of particles (if any) might be trapped within structures formed by the other substance.
- a next step may be to deposit E04 onto the powder in serecteffpTdc 's "Stft* a*qtf*6us binder liquid suitable to join particles to other particles.
- the aqueous binder liquid can be either pure water or water with a binder substance dissolved in it. As described elsewhere herein, there are two possible ways in which an aqueous binder liquid can bind powder particles.
- each drop is associated with a voxel (unit volume) of powder that may be considered to have the shape of a rectangular prism.
- the dimensions of the voxel are the drop-to-drop spacing which may be called delta x, the line-to-line spacing which may be called delta y, and the thickness of the powder layer, which may be called delta z.
- the voxel contains within it a total volume given by
- (delta x) * (delta y) * (delta z) Within the voxel is a certain amount of empty volume representing the space between powder particles, i.e., space not occupied by powder particles, given by (1 - pf) * (delta x) * (delta y) * (delta z) , where pf is the powder packing fraction.
- the ratio of the dispensed droplet volume to the empty volume in the voxel is the saturation parameter.
- the drop volume may be represented by Vd.
- the saturation parameter is given by Vd / ( (1 - pf) *
- the deposition of the aqueous binder liquid can be done at a saturation parameter as small as 10% to 20%. This range is substantially smaller than what is used in most three- dimensional printing, and this is useful in improving the dimensional resolution of the final product.
- powder layer deposition and binder liquid deposition onto the powder layer can be repeated as many times as needed, with appropriate deposition patterns at each layer, to produce a desired geometry. It is not necessary that the powder which is spread in any given layer be the same as the powder which is spread in other layers. The powder could differ in its composition, in particle sizes and particle size distributions, and in other respects.
- the powder in a given layer in the 3DP process could have a different organic-solvent-soluble substance (s) from what is in other layers.
- the powder in a given layer could have a different organic-solvent-insoluble substance or substances or could have more or fewer of such substances.
- the printed powder bed can be allowed E06 to dry as needed and then unbound powder can be removed, resulting in a preform.
- the particles of organic-solvent- soluble substance would not be joined directly to each other because only an organic solvent would be able to cause that, and the article has not yet been exposed to any organic solvent during this process.
- some particles would be joined to each other through the solidification of one or more substances which are soluble in water, which is the base liquid of the aqueous binder liquid. It is possible that particles be joined to each other through a combination of solidification of whatever binder substance (if any) may have been dissolved in the binder liquid, or through the at least partial dissolution of water-soluble particles in the powder bed followed by resolidification.
- the preform can be exposed E08 to vapor of an organic solvent in which the organic-solvent-soluble particles are soluble.
- This can be done at a suitable vapor concentration and for a suitable time and for suitable values of any other relevant parameters, to cause at least some joining of organic-solvent-soluble particles to other organic- solvent-soluble particles.
- a suitable vapor concentration and for a suitable time and for suitable values of any other relevant parameters, to cause at least some joining of organic-solvent-soluble particles to other organic- solvent-soluble particles.
- the article to be solvent-vapor-fused may be supported in such a way that the article does not contact the liquid chloroform region and yet is well exposed to chloroform vapor.
- particles of the organic- solvent-soluble substance (such as a polymer) absorb the organic solvent even from a vapor state and thereby become dissolved or at least softened.
- polycaprolactone can absorb chloroform vapor to an extent of 3 to 5 %.
- the presence of chloroform lowers the effective glass transition temperature of the polymer.
- Fig. 7 shows what the article looks like after printing with the aqueous binder liquid and drying, before solvent vapor fusing.
- the organic- solvent-insoluble particles 720 which are white, are shown fused together such as from dissolution in water followed by resolidification, or from solidification of a binder substance initially dissolved in the binder liquid.
- the organic- solvent-insoluble particles 722 form a somewhat continuous structure.
- organic-solvent-soluble particles shown shaded, are shown somewhat incorporated into the already-fused structure of the organic-solvent-insoluble particles, but are shown as being separate and distinct from each other because at this stage they have never been exposed to an organic solvent which would make them fuse to each other.
- Fig. 8 shows the appearance of the preform after exposure to solvent vapor. It is believed that the former individual particles 722 of organic-solvent-soluble substance have merged into each other and created a sort of film 822 on the surface of the structure formed by the organic-solvent- Insoluble 's"U'B'sta* sT 1
- the preform can be removed 610 from the organic solvent vapor and can be exposed for a sufficient time to conditions of substantially no concentration of organic solvent vapor, so that substantially all of the organic solvent which may have been absorbed into the preform can leave the preform.
- the films of polymer or organic-solvent-soluble substance will harden.
- the preform contains both a connected structure 720 of water-soluble substance and a connected structure 822 of organic-solvent-soluble substance, with the two connected structures being intertwined with each other. If insoluble particles (not shown) are present, it is believed that at least some of them can be held in place at least partly by the newly-formed structure 822 of organic- solvent-soluble substance.
- the preform can be exposed to water under conditions suitable to dissolve out 612 substantially all of the water-soluble material or particles 720. As shown in Fig. 9, this leaves the structure of organic-solvent-soluble substance 822, which may also contain particles of the insoluble substance if such particles were present in the original powder. The structure which remains is illustrated in Fig. 9. (For simplicity, insoluble particles have not been illustrated in these schematic illustrations.)
- the family of salts includes go&i a ( crnT' ⁇ Yi'rie 'a" ⁇ ::i ' ⁇ e ' ⁇ :;
- the family of sugars includes sucrose, fructose and lactose, among others. Various combinations of these materials have been used to form the powder for 3DP experiments such as are described elsewhere herein. The choice and proportion of the members of the salt and sugar families can be determined by balancing various properties based on observations.
- particles of sodium chloride have an ability to absorb a certain amount of moisture before they actually begin to form necks which would join particles to each other. This property may be of some help in limiting the spread of aqueous liquid in the powder bed. The rate of dissolution of sodium chloride in water could be described as moderate among the various substances tried.
- Fructose and sucrose exhibit fairly rapid dissolution in water, which can be useful for forming necks joining particles. Lactose exhibits slower dissolution in water, in comparison to fructose and sucrose. This property of slower dissolution can be useful for a different reason. While other substances such as fructose and sucrose may be significantly involved in the dissolution/resolidification process based on water, the lactose particles may continue to exist throughout that process in a fairly intact manner.
- the lactose particles as originally supplied in the powder may still have a significant presence at the time the solvent-vapor-softened polymer flows to attain its final state.
- the structure after aqueous binding may comprise lactose particles joined to each other by necks which are made primarily of one of the other, more water-soluble sugars.
- the lactose particles as originally supplied in the powder may significantly determine the size and size distribution of the pores which exist in the final product.
- the powder may further comprise particles of yet another substance which may have low solubility or substantially no solubility in water and also have low solubility or substantially no solubility in organic solvents.
- This substance may be designated the insoluble substance.
- insoluble substances include ceramics such as bioceramics including members of the calcium phosphate family such as tricalcium phosphate, such as substances which are useful for supporting the ingrowth of bone. The choice of whether to include an insoluble material such as tricalcium phosphate depends on whether that material is desired in the finished product.
- the particles of the water-soluble substance can have a respective particle size and particle size distribution, and the particles of the organic-solvent-soluble substance can have their own respective size and size distribution, which may be the same as or different from the size and size distribution of the water-soluble particles. Furthermore, if insoluble particles are present, those particles may have their own r"espe , ctf've l '- l is a fie ' M ⁇ * W ⁇ distribution which can have any relation to the other two particle sizes and size distributions. Any of these can be varied from layer to layer in the 3DP process.
- Sterilization may be accomplished by any of several means and sequences in relation to the overall manufacturing process.
- the overall manufacturing process may include terminal sterilization, such as by electron beam irradiation, gamma radiation, ethylene oxide, or other means.
- the biostructure can be infused with additional substances .
- This Example compares the microstructure of polymer structures which were 3D-printed using the water printing solvent vapor fusing of the present invention against the microstructure of polymer structures which were 3D-printed using conventional dispensing of liquid chloroform onto a powder bed operating using the dissolution/resolidification mechanism. Both powderbeds contained a water-soluble porogen for later leaching out as an aid to creating porosity in the finished biostructure.
- Figs. 4A, 4B and 4C illustrate the microstructure of the structure made by conventional 3DP with dispensed liquid chloroform.
- the powder used in this case was 80:20 NaCl: PCL, magnifications are X150, X250 and X650, respectively.
- FIGs. 2A, 2B and 2C The microstructure of an article of an invention disclosed herein is illustrated in Figs. 2A, 2B and 2C. (This was made by water printing solvent fusing according to the present invention.) The powder used in this case was 80:20 Sucrose: PCL, The liquid dispensed during the 3DP process was pure water. Figs. 2A, 2B and 2C show such an article at magnifications of x50, xl60 and x900, respectively.
- substantially all of the polymer has the morphology of a film 222 (Fig. 2B) which is somewhat randomly crinkled and perforated but is somewhat continuous.
- This basic polymeric structure is believed to come from polymer material which substantially dissolved or softened upon exposure to the chloroform vapor, and which then resolidified in the form shown upon removal of the chloroform.
- This example compares the macrostructure of polymer structures which were 3D-printed using the water printing solvent vapor fusing of the present invention against the macrostructure of polymer structures which were 3D-printed using conventional dispensing of liquid chloroform onto a powder bed operating using the dissolution/resolidification mechanism. Both powder beds contained a water-soluble porogen for later leaching out as an aid to creating porosity in the finished biostructure.
- Fig. 10 shows a face or top view of a structure. Actually, the two images in that figure are of not exactly the same part of a complicated structure.
- Fig. 11 (which is the same as Fig. 1) is a side view of the same features printed by the two different methods. It shows that sharper printing and better removal of unbound powder are achieved using a method of a present invention (on the right) as compared to a conventional printing process with liquid chloroform on the left.
- FIG. 12 compares printing onto the same powder bed composition with a pure water binder liquid (right) and printing with a binder liquid that is a solution of sucrose in water (left) . It is believed that the structure resulting from the sucrose solution printing is better held together, and the structure with pure water is more flaky. It is believed that the presence of the sucrose provides binding with less dependence on dissolution taking place during the 3DP process itself, and results in somewhat better filling of spaces between particles and attachment of particles to each other.
- sucrose solution has different wetting characteristics from plain water. It is believed that the sucrose solution causes more powder rearrangement (powder particles pulling closer to each other during the time when they are wet) , which means that the primitive features thus formed pull slightly away from the bulk powder, which results in better distinction between wet (printed) and dry (un-printed) regions, and hence less bleeding, and hence crisper and finer feature definition and also better structural characteristics.
- Example 4
- Figs. 13A-13E demonstrated printing with an aqueous binder liquid (pure water) onto a powder bed which comprised not only polymer and water-soluble material, but also tricalcium phosphate.
- the composition of the powder was 20% PCL (polycaprolactone), 20% TCP, 60% Sugar.
- the preform was exposed to solvent vapor fusing.
- solvent vapor fusing the sugar was leached out with water.
- Articles so made, shown in Fig. 13A and 13B at two different magnifications have a squeezability which can readily be felt, and they also contain tricalcium phosphate for encouraging bone ingrowth, and they also contain macrochannels 1330 as illustrated in Figs. 13A and 13B.
- Figs. 13C, 13D and 13E show the same sample at greater magnifications of X55, X400 and X750, respectively.
- a preform which contains organic-solvent-insoluble particles bound to each other and which further contains organic-solvent- soluble particles.
- a mixture of organic-solvent- soluble and organic-solvent-insoluble particles, possibly including a binder substance, can be formed into a desired shape by other means such as molding, casting, or other means, which can include removal of material (cutting) .
- the organic-solvent-insoluble particles can include water-soluble particles.
- water-soluble particles can include more than one substance which may be selected for their characteristics such as rate of dissolution in water, tendency to absorb water, etc. Different components may have their own particle size and particle size distribution.
- the organic-solvent-insoluble particles can be he oV t ⁇ g ' e't'-i ⁇ 'r"'"b ' y "'j Witting* each other or by an appropriate binder substance, any of which results in a preform.
- the organic-solvent-insoluble particles can also include insoluble particles as described elsewhere herein.
- the preform can be exposed 1452 to vapor of an organic solvent in which the organic-solvent-soluble particles are soluble. This can be done at a suitable vapor concentration and for a suitable time and for suitable values of any other relevant parameters, so as to cause at least some joining of organic-solvent-soluble particles to other organic-solvent-soluble particles. Then, the preform can be exposed P54 to conditions free of organic solvent so that organic solvent already in the preform can leave.
- the water-soluble substances can be leached out 1456.
- Fig. 15 illustrates the large-scale features which are the overall grid shape, which is defined by the 3DP process, and small-scale porosity (which are all the smaller features) , which are defined largely by the powder and related fusing and leaching steps, using water based printed binder and solvent film forming, or fusing.
- a second method of filming material it is possible to heat the bound preform to an appropriate temperature for an appropriate time such that the particles of a water insoluble, heat filmable material melt or soften and f ⁇ ot ⁇ bveV' ⁇ t ac l s ra o ⁇ , ' ': ,a fetructure formed by a water soluble heat resistant material to form a film.
- the temperature used for heat-filming may be selected to avoid causing thermal degradation of the polymers and any other substances present in the organic-solvent-soluble material. If the heat filmable material further includes bioactive substances such as one or more active pharmaceutical ingredient, a temperature for heat filming may be selected to avoid thermal damage to those substances as well.
- a duration for heat filming may also be selected suitable to result in a sufficient degree of filming. It is believed that at the filming temperature, the softened or liquefied heat filmable material will coalesce in a manner similar to that which has already been described for solvent vapor filming. When the preform is brought back to a lower temperature, the heat-filmed material will harden in its new configuration.
- a first type of powder that is soluble by a liquid solvent, such as water, but that is resistant to softening under heated conditions; and that there be a second particle material that is solvent-insoluble, but that is filmable upon heating.
- a liquid solvent such as water
- the desired shape can be printed in the particle bed with the liquid solvent, which causes initial joining of particles that the solvent has contacted, but not the insoluble particles.
- the liquid solvent may be water, or, alcohol, or an inorganic solvent or any solvent. Loose particles are removed. Then the entire body is heated to a temperature that causes filming of the heat filmable material, as described above.
- the solvent is again applied, but perhaps to a greater degree, to dissolve and remove all of the solvent soluble material from the structure, leaving only the heat filmable material.
- the solvent is an organic solvent
- the operator does get the advantages of a method of the invention described above, where a film is formed around a temporarily formed organic-solvent-soluble structure. [ud ⁇ 09] it" ⁇ '" p S ⁇ b e that both of the above two processes (solvent vapor filming, heat filming) could be performed, in combination and/or in sequence, to cause the desired filming of material.
- solvent vapor could be performed at a temperature warm enough so that the temperature also contributes to softening of a material that is both organic-solvent-soluble and heat flowable.
- a solvent vapor could be applied to cause initial softening and flowing, followed by elevated temperatures to cause further flowing of material.
- the elevated temperature could be applied first, followed by solvent vapor.
- Supercritical C0 2 is known to have solubility properties which can allow it to replace halogenated hydrocarbons and related organic solvents for cleaning purposes, and it is widely used for the extraction of caffeine from coffee and tea. Above critical temperature (31 °C) and critical pressure (72.8 atm) , the vapor and liquid phases of C0 2 become indistinguishable, and the resulting supercritical fluid substance undergoes significant increase in solvent power, and the solvency is known to be strongly dependent on the pressure.
- PLGA is believed to be soluble in supercritical C0 2 .
- the substance chosen for vapor fusing may comprise a non-halogenated substance such as supercritical carbon dioxide (C0 2 ) .
- C0 2 supercritical carbon dioxide
- the use of supercritical C0 2 would obviate the need for exposure of the biostructure to cytotoxic materials such as chloroform or methylene chloride.
- a subsequent treatment with supercritical C0 2 may be used to reduce the residual solvent level and improve safety and efficacy of the resulting biostructure.
- a general logic of a method invention hereof is to provide a bound preform that is composed of at least two different types of particles: one that is soluble by a first solvent or condition, but insoluble by a second solvent or condition; and a second that is the opposite, namely insoluble by the first solvent or condition but soluble by the second solvent or condition.
- soluble and insoluble are more restrictive than meant here in this generalization discussion.
- the first particulate material must respond to the first solvent or condition by forming a bound interconnected body with sufficient strength and integrity to withstand subsequent processing, and also must be such that particles of the second material bind to the formed interconnected body.
- the second particulate material must be substantially unresponsive and remain intact in response to the first solvent or condition, and must respond to the second solvent or condition by forming a film that is in close contact with the surface of the interconnected body formed by the first type of particles.
- the first type of particles must be unresponsive and remain bound and intact in the presence of the second solvent or condition, so that the second type of particles can flow and form a film that uses the bound first particle body as a form, or template.
- the first type of particles must further respond to the first solvent or condition, or a third solvent or condition to which the second type of particles, after formed into a film, remains intact, so that the bound body of first particles, in response to the first condition again, or a third condition, unbinds, dissolves or melts away, leaving only the film that formed from the second type of particles.
- [00114J of this aspect of an invention hereof uses the word condition to mean either a solvent (liquid or vapor) or other environmental condition, such as heat, and uses the word responsive to mean soluble, or filmable.
- the first condition is invoked, and a bound geometry is formed in the particle collection, from bound particles of the first type, to which are also bound particles of the second type. Particles that are not bound are removed.
- the second condition is invoked, and a film of the second type of particles forms closely following surfaces of the bound body of first type of particles.
- the first condition is invoked again, possibly in a different form. For instance the first instance of the first condition could have been printed water, and the subsequent instance of the first condition could be immersion in water. Or, rather than exploiting the same phenomena, after invoking the second condition, it is possible to invoke a related or different condition to which the first type of particles are responsive. In any case, the bound body of the first type of particles is removed.
- the articles of the present inventions can be used as substitutes for bone for repairing and healing osseous defects or for the conduction or induction of bone into a desired area such as a spinal cage. They can also be used as tissue scaffolds for growth of any sort of tissue either inside or outside the body.
- the springiness of the articles means that they might be able to be installed into a confined space by squeezing them and allowing them to spring back and fill space. For example, this could provide continuing contact force between the implant and the neighboring bone or other tissue, which would promote guided tissue growth.
- a compressible scaffold could be folded or rolled or compressed and delivered to a specified site in the compressed state.
- the springiness could promote a good fit to a defect and could limit undesired migration or micromotion. Flexibility of the scaffold could be particularly useful for reconstruction of soft tissue such as ligaments or breast tissue or cosmetic applications.
- a process of a present invention enables the production of porous articles whose networks or structures include materials that are only soluble in organic solvents, and those networks or structures can contain a considerable degree of geometric complexity (which is attainable only through three-dimensional printing) . Nevertheless, this process eliminates the need for dispensing of organic solvent from a printhead, which is a step fraught with some technical difficulties and, in the case of chloroform, requires printing at a saturation parameter which is not conducive to achieving fine feature sizes.
- a process of a present invention also eliminates the need for the entire operating region of the 3DP machine to be exposed to vapors of organic solvents such as chloroform and eliminates the need for the printhead fluid handling system to be designed for handling organic solvents such as chloroform.
- the printing parameters are determined largely by the properties of the water-soluble powders which can be printed upon with water-based binder liquids .
- Another feature of this invention which can be appreciated is that it decouples the polymer fusing from the three-dimensional printing.
- tissue engineering research many polymers are being experimented with for use as scaffolds. IhTHr ' ee 1 -dffi'e ⁇ si6 , h , W" ,, p ⁇ hting, it is known that adjustments and optimizations often have to be made which are unique to specific polymers and solvents and printing conditions.
- the fusing of the polymer into a structure occurs separately from the 3DP process.
- the 3DP process can be somewhat standardized based largely on the properties and composition of the organic-solvent- insoluble powder components (the sugars and salts) and their binder liquid (which might be as simple as pure water) .
- the 3DP process will not have to be adjusted each time the polymer may be changed, because the polymer is not really an active participant in the 3DP process, i.e., the polymer undergoes no significant physical or chemical change during the actual 3DP process. The undergoing of significant physical change by polymer occurs separately at a later step, and in a setting which is fairly simple.
- the principal variable influencing the vapor solvent fusing process is the time duration of exposure to the solvent vapor.
- the use of water-soluble particles which are later dissolved out helps to create pores of controlled size, and in particular is helpful for creating high porosity.
- the use of a mix of water-soluble particles some of which are less water-soluble than others helps to preserve the size of the less-water-soluble particles as templates for the creation of pores. Ordinarily in a dissolution/resolidification situation it would be difficult to preserve the size of particles as templates for the creation of pores .
- An article of an invention hereof can be used as a bone repair implant. It contains geometric features known to be conducive to bone ingrowth.
- the product can be squeezed and press-fitted into a cavity similar to the way in which foam earplugs can be compressed and inserted into the ear canal .
- Any empty space either at the size scale of pores or at the size scale of macroscopic polymer-free features, can contain useful biological substances, can contain useful biological substances including growth factors, cells, Active Pharmaceutical Ingredients, etc.
- 0OT22 and aspects of the inventions have been described herein. The person skilled in the art will understand that many of these techniques can be used with other disclosed techniques, even if they have not been specifically described in use together.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007513374A JP2007537007A (en) | 2004-05-12 | 2005-05-12 | Manufacturing methods such as three-dimensional printing including solvent vapor film formation |
CA002564605A CA2564605A1 (en) | 2004-05-12 | 2005-05-12 | Manufacturing process, such as three-dimensional printing, including solvent vapor filming and the like |
US11/579,783 US7815826B2 (en) | 2004-05-12 | 2005-05-12 | Manufacturing process, such as three-dimensional printing, including solvent vapor filming and the like |
EP05749496A EP1763703A4 (en) | 2004-05-12 | 2005-05-12 | Manufacturing process, such as three-dimensional printing, including solvent vapor filming and the like |
US12/899,033 US20110076762A1 (en) | 2004-05-12 | 2010-10-06 | Articles formed by manufacturing processes, such as three-dimensional printing, including solvent vapor filming and the like |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57041204P | 2004-05-12 | 2004-05-12 | |
US60/570,412 | 2004-05-12 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/899,033 Division US20110076762A1 (en) | 2004-05-12 | 2010-10-06 | Articles formed by manufacturing processes, such as three-dimensional printing, including solvent vapor filming and the like |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005114322A2 true WO2005114322A2 (en) | 2005-12-01 |
WO2005114322A3 WO2005114322A3 (en) | 2007-03-22 |
Family
ID=35429018
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/016698 WO2005114322A2 (en) | 2004-05-12 | 2005-05-12 | Manufacturing process, such as three-dimensional printing, including solvent vapor filming and the like |
PCT/US2005/016734 WO2005114323A2 (en) | 2004-05-12 | 2005-05-12 | Manufacturing process of three dimensional printing |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/016734 WO2005114323A2 (en) | 2004-05-12 | 2005-05-12 | Manufacturing process of three dimensional printing |
Country Status (5)
Country | Link |
---|---|
US (3) | US7815826B2 (en) |
EP (1) | EP1763703A4 (en) |
JP (1) | JP2007537007A (en) |
CA (1) | CA2564605A1 (en) |
WO (2) | WO2005114322A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009045176A1 (en) * | 2007-10-03 | 2009-04-09 | Bio-Scaffold International Pte Ltd | Method of making a scaffold for tissue and bone applications |
CN107548349A (en) * | 2015-06-10 | 2018-01-05 | 惠普发展公司有限责任合伙企业 | Build temperature modulation |
EP3778790A1 (en) * | 2014-05-15 | 2021-02-17 | Northwestern University | Ink compositions for three-dimensional printing and methods of forming objects using the ink compositions |
US11654214B2 (en) | 2013-08-02 | 2023-05-23 | Northwestern University | Ceramic-containing bioactive inks and printing methods for tissue engineering applications |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3009477B1 (en) | 2006-07-20 | 2024-01-24 | Orbusneich Medical Pte. Ltd | Bioabsorbable polymeric composition for a medical device |
EP2073754A4 (en) | 2006-10-20 | 2012-09-26 | Orbusneich Medical Inc | Bioabsorbable polymeric composition and medical device background |
US7959942B2 (en) | 2006-10-20 | 2011-06-14 | Orbusneich Medical, Inc. | Bioabsorbable medical device with coating |
US20100279007A1 (en) * | 2007-08-14 | 2010-11-04 | The Penn State Research Foundation | 3-D Printing of near net shape products |
US8685432B2 (en) * | 2008-03-25 | 2014-04-01 | University Of Utah Research Foundation | Controlled release tissue graft combination biomaterials |
GB0809721D0 (en) * | 2008-05-28 | 2008-07-02 | Univ Bath | Improvements in or relating to joints and/or implants |
WO2010011911A2 (en) * | 2008-07-25 | 2010-01-28 | Cornell University | Apparatus and methods for digital manufacturing |
SG178421A1 (en) | 2009-09-02 | 2012-04-27 | Akzo Nobel Chemicals Int Bv | Nitrogen- containing surfactants for agricultural use |
GB201003065D0 (en) * | 2010-02-23 | 2010-04-07 | Simpleware Ltd | Image processing method and method of three-dimensional printing incorporating the same |
IT1398443B1 (en) * | 2010-02-26 | 2013-02-22 | Lima Lto S P A Ora Limacorporate Spa | INTEGRATED PROSTHETIC ELEMENT |
JP5824955B2 (en) * | 2011-08-12 | 2015-12-02 | ソニー株式会社 | Manufacturing method of shaped objects |
US20130186558A1 (en) | 2011-09-23 | 2013-07-25 | Stratasys, Inc. | Layer transfusion with heat capacitor belt for additive manufacturing |
CA2847351C (en) | 2011-09-23 | 2017-02-21 | Stratasys, Inc. | Layer transfusion for additive manufacturing |
US8879957B2 (en) | 2011-09-23 | 2014-11-04 | Stratasys, Inc. | Electrophotography-based additive manufacturing system with reciprocating operation |
US8488994B2 (en) | 2011-09-23 | 2013-07-16 | Stratasys, Inc. | Electrophotography-based additive manufacturing system with transfer-medium service loops |
US9381112B1 (en) | 2011-10-06 | 2016-07-05 | William Eric Sponsell | Bleb drainage device, ophthalmological product and methods |
US8414654B1 (en) * | 2011-11-23 | 2013-04-09 | Amendia, Inc. | Bone implants and method of manufacture |
US8632489B1 (en) | 2011-12-22 | 2014-01-21 | A. Mateen Ahmed | Implantable medical assembly and methods |
WO2014018075A1 (en) | 2012-07-23 | 2014-01-30 | Crayola, Llc | Dissolvable films and methods of using the same |
JP6068921B2 (en) * | 2012-10-19 | 2017-01-25 | ホソカワミクロン株式会社 | Manufacturing method of drug eluting device |
US20140186441A1 (en) * | 2012-12-28 | 2014-07-03 | DePuy Synthes Products, LLC | Composites for Osteosynthesis |
WO2014123978A2 (en) | 2013-02-05 | 2014-08-14 | University Of Utah Research Foundation | Implantable devices for bone or joint defects |
GB2515510B (en) | 2013-06-25 | 2019-12-25 | Synopsys Inc | Image processing method |
CN103341989B (en) * | 2013-07-08 | 2015-07-29 | 上海大学 | The comprehensive Regenerated Bone stent forming System and method for be shaped is printed based on 3D |
US9144940B2 (en) | 2013-07-17 | 2015-09-29 | Stratasys, Inc. | Method for printing 3D parts and support structures with electrophotography-based additive manufacturing |
US9029058B2 (en) | 2013-07-17 | 2015-05-12 | Stratasys, Inc. | Soluble support material for electrophotography-based additive manufacturing |
US9023566B2 (en) | 2013-07-17 | 2015-05-05 | Stratasys, Inc. | ABS part material for electrophotography-based additive manufacturing |
US10471497B2 (en) | 2013-08-16 | 2019-11-12 | The Exone Company | Three-dimensional printed metal-casting molds and methods for making the same |
US20160243621A1 (en) | 2013-10-17 | 2016-08-25 | The Exone Company | Three-Dimensional Printed Hot Isostatic Pressing Containers and Processes for Making Same |
AU2014357315B2 (en) | 2013-11-27 | 2018-05-17 | Adaptiiv Medical Technologies Inc. | System and method for manufacturing bolus for radiotherapy using a three-dimensional printer |
EP3086922B1 (en) | 2013-12-23 | 2022-03-09 | The Exone Company | Method of three-dimensional printing using a multi-component build powder |
US20160332373A1 (en) | 2013-12-23 | 2016-11-17 | The Exone Company | Methods and Systems for Three-Dimensional Printing Utilizing Multiple Binder Fluids |
US11060057B2 (en) * | 2014-03-11 | 2021-07-13 | University Of South Carolina | Presaturation of supercritical CO2 with water for decellularization of matrices |
US9487443B2 (en) * | 2014-03-14 | 2016-11-08 | Ricoh Company, Ltd. | Layer stack formation powder material, powder layer stack formation hardening liquid, layer stack formation material set, and layer stack object formation method |
US10011071B2 (en) | 2014-03-18 | 2018-07-03 | Evolve Additive Solutions, Inc. | Additive manufacturing using density feedback control |
US9770869B2 (en) | 2014-03-18 | 2017-09-26 | Stratasys, Inc. | Additive manufacturing with virtual planarization control |
US10144175B2 (en) | 2014-03-18 | 2018-12-04 | Evolve Additive Solutions, Inc. | Electrophotography-based additive manufacturing with solvent-assisted planarization |
US9643357B2 (en) | 2014-03-18 | 2017-05-09 | Stratasys, Inc. | Electrophotography-based additive manufacturing with powder density detection and utilization |
US9868255B2 (en) | 2014-03-18 | 2018-01-16 | Stratasys, Inc. | Electrophotography-based additive manufacturing with pre-sintering |
US9688027B2 (en) | 2014-04-01 | 2017-06-27 | Stratasys, Inc. | Electrophotography-based additive manufacturing with overlay control |
US9919479B2 (en) | 2014-04-01 | 2018-03-20 | Stratasys, Inc. | Registration and overlay error correction of electrophotographically formed elements in an additive manufacturing system |
EP3142851B1 (en) | 2014-05-12 | 2019-07-10 | 3D Systems, Inc. | System and method for fabricating custom medical implant devices |
EP3148730A1 (en) | 2014-05-29 | 2017-04-05 | The Exone Company | Process for making nickel-based superalloy articles by three-dimensional printing |
WO2016011098A2 (en) | 2014-07-17 | 2016-01-21 | The Exone Company | Methods and apparatuses for curing three-dimensional printed articles |
US10821573B2 (en) | 2014-10-17 | 2020-11-03 | Applied Materials, Inc. | Polishing pads produced by an additive manufacturing process |
KR20240015167A (en) | 2014-10-17 | 2024-02-02 | 어플라이드 머티어리얼스, 인코포레이티드 | Cmp pad construction with composite material properties using additive manufacturing processes |
US10875145B2 (en) | 2014-10-17 | 2020-12-29 | Applied Materials, Inc. | Polishing pads produced by an additive manufacturing process |
US11745302B2 (en) | 2014-10-17 | 2023-09-05 | Applied Materials, Inc. | Methods and precursor formulations for forming advanced polishing pads by use of an additive manufacturing process |
US10875153B2 (en) | 2014-10-17 | 2020-12-29 | Applied Materials, Inc. | Advanced polishing pad materials and formulations |
US10399201B2 (en) * | 2014-10-17 | 2019-09-03 | Applied Materials, Inc. | Advanced polishing pads having compositional gradients by use of an additive manufacturing process |
EP3218160A4 (en) | 2014-11-14 | 2018-10-17 | Nielsen-Cole, Cole | Additive manufacturing techniques and systems to form composite materials |
WO2016089618A1 (en) | 2014-12-03 | 2016-06-09 | The Exone Company | Process for making densified carbon articles by three dimensional printing |
WO2016175832A1 (en) | 2015-04-30 | 2016-11-03 | Hewlett-Packard Development Company, L.P. | Three-dimensional (3d) printing |
JP6573510B2 (en) * | 2015-09-11 | 2019-09-11 | 日本碍子株式会社 | Porous material manufacturing method and manufacturing apparatus |
US10449624B2 (en) | 2015-10-02 | 2019-10-22 | Board Of Regents, The University Of Texas System | Method of fabrication for the repair and augmentation of part functionality of metallic components |
EP3359594A4 (en) * | 2015-10-09 | 2019-07-03 | Hewlett-Packard Development Company, L.P. | Particulate mixtures |
US10391605B2 (en) | 2016-01-19 | 2019-08-27 | Applied Materials, Inc. | Method and apparatus for forming porous advanced polishing pads using an additive manufacturing process |
EP3436248B1 (en) | 2016-07-04 | 2022-10-05 | Hewlett-Packard Development Company, L.P. | Preparing a base for additive manufacturing |
US11046823B2 (en) * | 2016-08-03 | 2021-06-29 | Wake Forest University Health Sciences | Composition with polymer and ceramic and methods of use thereof |
US10595990B2 (en) | 2016-09-06 | 2020-03-24 | Gyrus Acmi, Inc. | Osseointegrative adjustable ossicular prosthesis |
US10576395B2 (en) | 2017-03-14 | 2020-03-03 | University Of South Carolina | Supercritical carbon dioxide extraction of residual glutaraldehyde from crosslinked collagen |
US10435576B2 (en) | 2017-05-26 | 2019-10-08 | Infinite Material Solutions, Llc | Water soluble polymer compositions |
US11471999B2 (en) | 2017-07-26 | 2022-10-18 | Applied Materials, Inc. | Integrated abrasive polishing pads and manufacturing methods |
WO2019032286A1 (en) | 2017-08-07 | 2019-02-14 | Applied Materials, Inc. | Abrasive delivery polishing pads and manufacturing methods thereof |
US11351724B2 (en) | 2017-10-03 | 2022-06-07 | General Electric Company | Selective sintering additive manufacturing method |
US11420384B2 (en) | 2017-10-03 | 2022-08-23 | General Electric Company | Selective curing additive manufacturing method |
US11590691B2 (en) | 2017-11-02 | 2023-02-28 | General Electric Company | Plate-based additive manufacturing apparatus and method |
US11254052B2 (en) | 2017-11-02 | 2022-02-22 | General Electric Company | Vatless additive manufacturing apparatus and method |
US10821668B2 (en) | 2018-01-26 | 2020-11-03 | General Electric Company | Method for producing a component layer-by- layer |
US10821669B2 (en) | 2018-01-26 | 2020-11-03 | General Electric Company | Method for producing a component layer-by-layer |
US10774909B2 (en) | 2018-03-28 | 2020-09-15 | Valeo Kapec Co., Ltd. | Method for making turbine wheel of hydrokinetic torque converter |
CN112654655A (en) | 2018-09-04 | 2021-04-13 | 应用材料公司 | Advanced polishing pad formulations |
US11794412B2 (en) | 2019-02-20 | 2023-10-24 | General Electric Company | Method and apparatus for layer thickness control in additive manufacturing |
US11498283B2 (en) | 2019-02-20 | 2022-11-15 | General Electric Company | Method and apparatus for build thickness control in additive manufacturing |
US11179891B2 (en) | 2019-03-15 | 2021-11-23 | General Electric Company | Method and apparatus for additive manufacturing with shared components |
US11179577B2 (en) | 2019-04-26 | 2021-11-23 | Adaptiv Medical Technologies Inc. | Systems and methods for hot spot reduction during design and manufacture of radiation therapy bolus |
US11813712B2 (en) | 2019-12-20 | 2023-11-14 | Applied Materials, Inc. | Polishing pads having selectively arranged porosity |
US11806829B2 (en) | 2020-06-19 | 2023-11-07 | Applied Materials, Inc. | Advanced polishing pads and related polishing pad manufacturing methods |
US11878389B2 (en) | 2021-02-10 | 2024-01-23 | Applied Materials, Inc. | Structures formed using an additive manufacturing process for regenerating surface texture in situ |
US11951679B2 (en) | 2021-06-16 | 2024-04-09 | General Electric Company | Additive manufacturing system |
US11731367B2 (en) | 2021-06-23 | 2023-08-22 | General Electric Company | Drive system for additive manufacturing |
US11826950B2 (en) | 2021-07-09 | 2023-11-28 | General Electric Company | Resin management system for additive manufacturing |
US11813799B2 (en) | 2021-09-01 | 2023-11-14 | General Electric Company | Control systems and methods for additive manufacturing |
Family Cites Families (167)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3566871A (en) | 1968-06-11 | 1971-03-02 | American Cyanamid Co | Hydrophilic medical sponge and method of using same |
US4057537A (en) | 1975-01-28 | 1977-11-08 | Gulf Oil Corporation | Copolymers of L-(-)-lactide and epsilon caprolactone |
US4045418A (en) | 1975-01-28 | 1977-08-30 | Gulf Oil Corporation | Copolymers of D,L-lactide and epsilon caprolactone |
US4186448A (en) * | 1976-04-16 | 1980-02-05 | Brekke John H | Device and method for treating and healing a newly created bone void |
US4243775A (en) | 1978-11-13 | 1981-01-06 | American Cyanamid Company | Synthetic polyester surgical articles |
US4137921A (en) * | 1977-06-24 | 1979-02-06 | Ethicon, Inc. | Addition copolymers of lactide and glycolide and method of preparation |
US4547327A (en) | 1980-12-08 | 1985-10-15 | Medical Biological Sciences, Inc. | Method for producing a porous prosthesis |
US4379138A (en) | 1981-12-28 | 1983-04-05 | Research Triangle Institute | Biodegradable polymers of lactones |
US4605730A (en) | 1982-10-01 | 1986-08-12 | Ethicon, Inc. | Surgical articles of copolymers of glycolide and ε-caprolactone and methods of producing the same |
US4700704A (en) | 1982-10-01 | 1987-10-20 | Ethicon, Inc. | Surgical articles of copolymers of glycolide and ε-caprolactone and methods of producing the same |
US4673355A (en) | 1982-10-25 | 1987-06-16 | Farris Edward T | Solid calcium phosphate materials |
US4643734A (en) * | 1983-05-05 | 1987-02-17 | Hexcel Corporation | Lactide/caprolactone polymer, method of making the same, composites thereof, and prostheses produced therefrom |
US4650488A (en) * | 1984-05-16 | 1987-03-17 | Richards Medical Company | Biodegradable prosthetic device |
US4637931A (en) | 1984-10-09 | 1987-01-20 | The United States Of America As Represented By The Secretary Of The Army | Polyactic-polyglycolic acid copolymer combined with decalcified freeze-dried bone for use as a bone repair material |
US4595713A (en) | 1985-01-22 | 1986-06-17 | Hexcel Corporation | Medical putty for tissue augmentation |
US4636526A (en) | 1985-02-19 | 1987-01-13 | The Dow Chemical Company | Composites of unsintered calcium phosphates and synthetic biodegradable polymers useful as hard tissue prosthetics |
JP2551756B2 (en) * | 1985-05-07 | 1996-11-06 | 武田薬品工業株式会社 | Polyoxycarboxylic acid ester and method for producing the same |
US4728570A (en) * | 1985-10-29 | 1988-03-01 | United States Surgical Corporation | Calcium-hydroxide-treated polymeric implant matrial |
US4780450A (en) | 1985-12-20 | 1988-10-25 | The University Of Maryland At Baltimore | Physically stable composition and method of use thereof for osseous repair |
DE3613213A1 (en) | 1986-04-18 | 1987-10-22 | Merck Patent Gmbh | TRICALCIUMPHOSPHATE FOR IMPLANTATION MATERIALS |
US4719246A (en) | 1986-12-22 | 1988-01-12 | E. I. Du Pont De Nemours And Company | Polylactide compositions |
US4800219A (en) * | 1986-12-22 | 1989-01-24 | E. I. Du Pont De Nemours And Company | Polylactide compositions |
US4843112A (en) * | 1987-03-12 | 1989-06-27 | The Beth Israel Hospital Association | Bioerodable implant composition |
JP2572606B2 (en) | 1987-09-14 | 1997-01-16 | 旭光学工業株式会社 | Manufacturing method of superficially porous calcium phosphate ceramics |
DE3826915A1 (en) | 1988-08-09 | 1990-02-15 | Henkel Kgaa | NEW MATERIALS FOR BONE REPLACEMENT AND BONE OR PROSTHESIS COMPOSITION |
JP2672589B2 (en) | 1988-08-31 | 1997-11-05 | 出光興産株式会社 | Styrene-based polymer molded article and method for producing the same |
US5250584A (en) | 1988-08-31 | 1993-10-05 | G-C Dental Industrial Corp. | Periodontium-regenerative materials |
AU5154390A (en) | 1989-02-15 | 1990-09-05 | Microtek Medical, Inc. | Biocompatible material and prosthesis |
DE3937272A1 (en) | 1989-11-09 | 1991-05-16 | Boehringer Ingelheim Kg | NEW COPOLYMERS FROM TRIMETHYLENE CARBONATE AND OPTICALLY INACTIVE LACTIDS |
US5387380A (en) | 1989-12-08 | 1995-02-07 | Massachusetts Institute Of Technology | Three-dimensional printing techniques |
US5204055A (en) | 1989-12-08 | 1993-04-20 | Massachusetts Institute Of Technology | Three-dimensional printing techniques |
US4994074A (en) * | 1990-02-01 | 1991-02-19 | Ethicon, Inc. | Copolymers of ε-caprolactone, glycolide and glycolic acid for suture coatings |
US5133739A (en) | 1990-02-06 | 1992-07-28 | Ethicon, Inc. | Segmented copolymers of ε-caprolactone and glycolide |
US5492697A (en) * | 1990-03-05 | 1996-02-20 | Board Of Regents, Univ. Of Texas System | Biodegradable implant for fracture nonunions |
US7208013B1 (en) | 1990-06-28 | 2007-04-24 | Bonutti Ip, Llc | Composite surgical devices |
US5593425A (en) * | 1990-06-28 | 1997-01-14 | Peter M. Bonutti | Surgical devices assembled using heat bonable materials |
DE69120177T2 (en) | 1990-09-10 | 1996-10-10 | Synthes Ag | Bone regeneration membrane |
US5034422A (en) | 1990-12-19 | 1991-07-23 | Foamex Lp | Low density, high temperature resistant polymeric bodies |
US5348788A (en) | 1991-01-30 | 1994-09-20 | Interpore Orthopaedics, Inc. | Mesh sheet with microscopic projections and holes |
US5320624A (en) | 1991-02-12 | 1994-06-14 | United States Surgical Corporation | Blends of glycolide and/or lactide polymers and caprolactone and/or trimethylene carbonate polymers and absorbable surgical devices made therefrom |
US6228954B1 (en) | 1991-02-12 | 2001-05-08 | United States Surgical Corporation | Blends of glycolide and/or lactide polymers and caprolactone and/or trimethylene carbonate polymers and absorabable surgical devices made therefrom |
CA2070586C (en) | 1991-06-10 | 1995-11-28 | Barry Eppley | Prosthetic implant |
DE4120325A1 (en) | 1991-06-20 | 1992-12-24 | Merck Patent Gmbh | IMPLANT MATERIAL |
US5356629A (en) | 1991-07-12 | 1994-10-18 | United States Surgical Corporation | Composition for effecting bone repair |
JPH0557713A (en) * | 1991-09-05 | 1993-03-09 | Toyota Motor Corp | Method for molding of fine pieces |
US5219897A (en) | 1992-02-10 | 1993-06-15 | Murray William M | Dental and orthopedic cement method and preforms |
US6013853A (en) | 1992-02-14 | 2000-01-11 | The University Of Texas System | Continuous release polymeric implant carrier |
JPH07503869A (en) | 1992-02-14 | 1995-04-27 | ボード・オヴ・リージェンツ,ザ・ユニヴァーシティ・オヴ・テキサス・システム | Multiphasic bioerodible implant materials or carriers and methods of manufacture and use thereof |
US5876452A (en) | 1992-02-14 | 1999-03-02 | Board Of Regents, University Of Texas System | Biodegradable implant |
US5573934A (en) | 1992-04-20 | 1996-11-12 | Board Of Regents, The University Of Texas System | Gels for encapsulation of biological materials |
FR2689400B1 (en) | 1992-04-03 | 1995-06-23 | Inoteb | BONE PROSTHESIS MATERIAL CONTAINING CALCIUM CARBONATE PARTICLES DISPERSED IN A BIORESORBABLE POLYMER MATRIX. |
US5366756A (en) | 1992-06-15 | 1994-11-22 | United States Surgical Corporation | Method for treating bioabsorbable implant material |
US5322925A (en) | 1992-10-30 | 1994-06-21 | United States Surgical Corporation | Absorbable block copolymers and surgical articles made therefrom |
US5333042A (en) | 1992-12-14 | 1994-07-26 | Interscience Computer Corporation | Cold fusing agent |
US5514378A (en) | 1993-02-01 | 1996-05-07 | Massachusetts Institute Of Technology | Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures |
DE4313192C1 (en) | 1993-04-22 | 1994-09-15 | Kirsch Axel | Cuff for accelerating healing of bone defects |
US5403347A (en) * | 1993-05-27 | 1995-04-04 | United States Surgical Corporation | Absorbable block copolymers and surgical articles fabricated therefrom |
US5442033A (en) | 1993-07-20 | 1995-08-15 | Ethicon, Inc. | Liquid copolymers of epsilon-caprolactone and lactide |
US5522895A (en) | 1993-07-23 | 1996-06-04 | Rice University | Biodegradable bone templates |
EP0713364A4 (en) | 1993-08-13 | 1996-12-27 | Shalaby W Shalaby | Microporous polymeric foams and microtextured surfaces |
US5466262A (en) | 1993-08-30 | 1995-11-14 | Saffran; Bruce N. | Malleable fracture stabilization device with micropores for directed drug delivery |
US5531794A (en) | 1993-09-13 | 1996-07-02 | Asahi Kogaku Kogyo Kabushiki Kaisha | Ceramic device providing an environment for the promotion and formation of new bone |
CA2149900C (en) | 1993-09-24 | 2003-06-24 | Yasuo Shikinami | Implant material |
US6176874B1 (en) * | 1993-10-18 | 2001-01-23 | Masschusetts Institute Of Technology | Vascularized tissue regeneration matrices formed by solid free form fabrication techniques |
US5518680A (en) * | 1993-10-18 | 1996-05-21 | Massachusetts Institute Of Technology | Tissue regeneration matrices by solid free form fabrication techniques |
US5490962A (en) | 1993-10-18 | 1996-02-13 | Massachusetts Institute Of Technology | Preparation of medical devices by solid free-form fabrication methods |
DE4403509A1 (en) | 1994-02-04 | 1995-08-10 | Draenert Klaus | Material and process for its manufacture |
US5686091A (en) | 1994-03-28 | 1997-11-11 | The Johns Hopkins University School Of Medicine | Biodegradable foams for cell transplantation |
US5626861A (en) * | 1994-04-01 | 1997-05-06 | Massachusetts Institute Of Technology | Polymeric-hydroxyapatite bone composite |
US5947893A (en) | 1994-04-27 | 1999-09-07 | Board Of Regents, The University Of Texas System | Method of making a porous prothesis with biodegradable coatings |
DE4414675C1 (en) | 1994-04-27 | 1995-09-28 | Kirsch Axel | Covering device for bone defects and method for their production |
US5639402A (en) * | 1994-08-08 | 1997-06-17 | Barlow; Joel W. | Method for fabricating artificial bone implant green parts |
US5769899A (en) | 1994-08-12 | 1998-06-23 | Matrix Biotechnologies, Inc. | Cartilage repair unit |
TW369414B (en) | 1994-09-30 | 1999-09-11 | Yamanouchi Pharma Co Ltd | Bone formation transplant |
US6376573B1 (en) * | 1994-12-21 | 2002-04-23 | Interpore International | Porous biomaterials and methods for their manufacture |
US5674290A (en) | 1995-04-05 | 1997-10-07 | Li; Shu-Tung | Water-stabilized biopolymeric implants |
US5834150A (en) | 1995-08-11 | 1998-11-10 | Interscience Computer Corporation | Solvent vapor fixing methods and process color toners for use in same |
US5747637A (en) | 1995-09-07 | 1998-05-05 | Mitsui Toatsu Chemicals, Inc. | Bioabsorbable polymer and process for preparing the same |
US5716413A (en) | 1995-10-11 | 1998-02-10 | Osteobiologics, Inc. | Moldable, hand-shapable biodegradable implant material |
US5776193A (en) * | 1995-10-16 | 1998-07-07 | Orquest, Inc. | Bone grafting matrix |
IT1278868B1 (en) * | 1995-10-27 | 1997-11-28 | Sanitaria Scaligera Spa | METHOD FOR OBTAINING A REABSORBABLE MATERIAL SUITABLE TO BE USED AS A COATING ELEMENT FOR THE PREVENTION OF |
EP0786259B1 (en) | 1996-01-19 | 2004-03-31 | United States Surgical Corporation | Absorbable polymer blends and surgical articles fabricated therefrom |
CA2252860C (en) | 1996-05-28 | 2011-03-22 | 1218122 Ontario Inc. | Resorbable implant biomaterial made of condensed calcium phosphate particles |
US5919234A (en) | 1996-08-19 | 1999-07-06 | Macropore, Inc. | Resorbable, macro-porous, non-collapsing and flexible membrane barrier for skeletal repair and regeneration |
US5866155A (en) | 1996-11-20 | 1999-02-02 | Allegheny Health, Education And Research Foundation | Methods for using microsphere polymers in bone replacement matrices and composition produced thereby |
US5769935A (en) | 1996-11-26 | 1998-06-23 | Alliedsignal Inc. | Use of fluorocarbons as a fusing agent for toners in laser printers |
AU5596898A (en) | 1996-12-03 | 1998-06-29 | Osteobiologics, Inc. | Biodegradable polymeric film |
FR2758988B1 (en) | 1997-02-05 | 2000-01-21 | S H Ind | PROCESS FOR THE PREPARATION OF SYNTHETIC BONE SUBSTITUTES OF PERFECTLY MASTERED POROUS ARCHITECTURE |
US7192450B2 (en) | 2003-05-21 | 2007-03-20 | Dexcom, Inc. | Porous membranes for use with implantable devices |
US6341952B2 (en) * | 1997-03-20 | 2002-01-29 | Therics, Inc. | Fabrication of tissue products with additives by casting or molding using a mold formed by solid free-form methods |
CA2288201A1 (en) | 1997-03-31 | 1998-10-08 | Therics, Inc. | Method for dispensing of powders |
US6213168B1 (en) * | 1997-03-31 | 2001-04-10 | Therics, Inc. | Apparatus and method for dispensing of powders |
US5977204A (en) * | 1997-04-11 | 1999-11-02 | Osteobiologics, Inc. | Biodegradable implant material comprising bioactive ceramic |
DE69805920T2 (en) | 1997-07-16 | 2003-01-02 | Isotis Nv | Bone treatment device consisting of degradable thermoplastic copolyester and cultured cells |
US6471993B1 (en) | 1997-08-01 | 2002-10-29 | Massachusetts Institute Of Technology | Three-dimensional polymer matrices |
US6241771B1 (en) | 1997-08-13 | 2001-06-05 | Cambridge Scientific, Inc. | Resorbable interbody spinal fusion devices |
US6296667B1 (en) | 1997-10-01 | 2001-10-02 | Phillips-Origen Ceramic Technology, Llc | Bone substitutes |
US6277927B1 (en) | 1997-11-26 | 2001-08-21 | United States Surgical Corporation | Absorbable block copolymers and surgical articles fabricated therefrom |
US6712851B1 (en) | 1998-01-23 | 2004-03-30 | Macropore Biosurgery, Inc. | Resorbable, macro-porous non-collapsing and flexible membrane barrier for skeletal repair and regeneration |
US6872387B1 (en) * | 1998-02-24 | 2005-03-29 | The Regents Of The University Of Michigan | Three-dimensional hydrogel/cell system |
US6494898B1 (en) | 1998-02-25 | 2002-12-17 | United States Surgical Corporation | Absorbable copolymers and surgical articles fabricated therefrom |
JP3360810B2 (en) * | 1998-04-14 | 2003-01-07 | ペンタックス株式会社 | Method for producing bone replacement material |
US6281257B1 (en) | 1998-04-27 | 2001-08-28 | The Regents Of The University Of Michigan | Porous composite materials |
US7063726B2 (en) | 1998-06-30 | 2006-06-20 | Lifenet | Plasticized bone grafts and methods of making and using same |
US6406498B1 (en) | 1998-09-04 | 2002-06-18 | Bionx Implants Oy | Bioactive, bioabsorbable surgical composite material |
ATE228021T1 (en) * | 1998-09-11 | 2002-12-15 | Gerhard Dr Schmidmaier | BIOLOGICALLY ACTIVE IMPLANTS |
US6146892A (en) | 1998-09-28 | 2000-11-14 | The Regents Of The University Of Michigan | Fibrillar matrices |
US20030114936A1 (en) * | 1998-10-12 | 2003-06-19 | Therics, Inc. | Complex three-dimensional composite scaffold resistant to delimination |
US6454811B1 (en) * | 1998-10-12 | 2002-09-24 | Massachusetts Institute Of Technology | Composites for tissue regeneration and methods of manufacture thereof |
US7022522B2 (en) * | 1998-11-13 | 2006-04-04 | Limin Guan | Macroporous polymer scaffold containing calcium phosphate particles |
US6283997B1 (en) | 1998-11-13 | 2001-09-04 | The Trustees Of Princeton University | Controlled architecture ceramic composites by stereolithography |
US6165486A (en) | 1998-11-19 | 2000-12-26 | Carnegie Mellon University | Biocompatible compositions and methods of using same |
US6110484A (en) | 1998-11-24 | 2000-08-29 | Cohesion Technologies, Inc. | Collagen-polymer matrices with differential biodegradability |
WO2000034204A1 (en) * | 1998-12-10 | 2000-06-15 | Robert Bosch Gmbh | Polymer compound, the production and use thereof, and sintered compacts produced therefrom |
US6147135A (en) | 1998-12-31 | 2000-11-14 | Ethicon, Inc. | Fabrication of biocompatible polymeric composites |
US6656489B1 (en) | 1999-02-10 | 2003-12-02 | Isotis N.V. | Scaffold for tissue engineering cartilage having outer surface layers of copolymer and ceramic material |
US6294187B1 (en) | 1999-02-23 | 2001-09-25 | Osteotech, Inc. | Load-bearing osteoimplant, method for its manufacture and method of repairing bone using same |
US6342065B1 (en) * | 1999-03-17 | 2002-01-29 | Poly-Med, Inc. | High strength fibers of L-lactide copolymers ε-caprolactone and trimethylene carbonate and absorbable medical constructs thereof |
US7371400B2 (en) | 2001-01-02 | 2008-05-13 | The General Hospital Corporation | Multilayer device for tissue engineering |
US6306424B1 (en) | 1999-06-30 | 2001-10-23 | Ethicon, Inc. | Foam composite for the repair or regeneration of tissue |
US6333029B1 (en) | 1999-06-30 | 2001-12-25 | Ethicon, Inc. | Porous tissue scaffoldings for the repair of regeneration of tissue |
US6458162B1 (en) | 1999-08-13 | 2002-10-01 | Vita Special Purpose Corporation | Composite shaped bodies and methods for their production and use |
US6441073B1 (en) | 1999-08-17 | 2002-08-27 | Taki Chemical Co., Ltd. | Biological materials |
US6206924B1 (en) | 1999-10-20 | 2001-03-27 | Interpore Cross Internat | Three-dimensional geometric bio-compatible porous engineered structure for use as a bone mass replacement or fusion augmentation device |
US7004977B2 (en) * | 1999-11-24 | 2006-02-28 | A Enterprises, Inc. | Soft tissue substitute and method of soft tissue reformation |
US6520997B1 (en) | 1999-12-08 | 2003-02-18 | Baxter International Inc. | Porous three dimensional structure |
US6982058B2 (en) | 1999-12-08 | 2006-01-03 | Baxter International, Inc. | Method for fabricating three dimensional structures |
US7592017B2 (en) * | 2000-03-10 | 2009-09-22 | Mast Biosurgery Ag | Resorbable thin membranes |
WO2001087575A2 (en) * | 2000-05-12 | 2001-11-22 | The Regents Of The University Of Michigan | Reverse fabrication of porous materials |
PT1310517E (en) | 2000-08-07 | 2006-05-31 | Wako Pure Chem Ind Ltd | LACTICAL ACID POLYMER AND PROCESS FOR ITS PRODUCTION |
US6506213B1 (en) * | 2000-09-08 | 2003-01-14 | Ferro Corporation | Manufacturing orthopedic parts using supercritical fluid processing techniques |
US7045125B2 (en) | 2000-10-24 | 2006-05-16 | Vita Special Purpose Corporation | Biologically active composites and methods for their production and use |
KR100408458B1 (en) | 2000-12-27 | 2003-12-06 | 한국과학기술연구원 | Porous Scaffolds for Tissue Engineering made from the Biodegradable Glycolide/ε-Caprolactone Copolymer |
US20020115742A1 (en) | 2001-02-22 | 2002-08-22 | Trieu Hai H. | Bioactive nanocomposites and methods for their use |
US6949251B2 (en) | 2001-03-02 | 2005-09-27 | Stryker Corporation | Porous β-tricalcium phosphate granules for regeneration of bone tissue |
US6913765B2 (en) | 2001-03-21 | 2005-07-05 | Scimed Life Systems, Inc. | Controlling resorption of bioresorbable medical implant material |
US6719795B1 (en) | 2001-04-25 | 2004-04-13 | Macropore Biosurgery, Inc. | Resorbable posterior spinal fusion system |
WO2003000480A1 (en) * | 2001-06-22 | 2003-01-03 | The Regents Of The University Of Michigan | Methods of designing and fabricating molds |
US7174282B2 (en) * | 2001-06-22 | 2007-02-06 | Scott J Hollister | Design methodology for tissue engineering scaffolds and biomaterial implants |
US6747121B2 (en) | 2001-09-05 | 2004-06-08 | Synthes (Usa) | Poly(L-lactide-co-glycolide) copolymers, methods for making and using same, and devices containing same |
EP1293220B1 (en) | 2001-09-13 | 2006-11-08 | Akira Myoi | Porous calcium phosphate ceramics for in vivo use |
US7509240B2 (en) * | 2001-10-15 | 2009-03-24 | The Regents Of The University Of Michigan | Solid freeform fabrication of structurally engineered multifunctional devices |
US7151120B2 (en) | 2001-10-17 | 2006-12-19 | The Regents Of The University Of Michigan | Degradable porous materials with high surface areas |
KR100453130B1 (en) | 2001-11-21 | 2004-10-15 | 한국과학기술연구원 | Sequentially Ordered Biodegradable Lactide(Glycolide or Lactide/Glycolide)/ε-Caprolactone Multi-Block Copolymer and Process for the Preparation Thereof |
US6712850B2 (en) * | 2001-11-30 | 2004-03-30 | Ethicon, Inc. | Porous tissue scaffolds for the repair and regeneration of dermal tissue |
JP2005511216A (en) * | 2001-12-12 | 2005-04-28 | デピュイ・プロダクツ・インコーポレイテッド | Orthopedic device and manufacturing method thereof |
US7575759B2 (en) * | 2002-01-02 | 2009-08-18 | The Regents Of The University Of Michigan | Tissue engineering scaffolds |
EP1499267A4 (en) | 2002-02-05 | 2008-10-29 | Depuy Mitek Inc | Bioresorbable osteoconductive compositions for bone regeneration |
FI118172B (en) | 2002-04-22 | 2007-08-15 | Inion Ltd | Surgical implant |
US7166133B2 (en) * | 2002-06-13 | 2007-01-23 | Kensey Nash Corporation | Devices and methods for treating defects in the tissue of a living being |
US7041309B2 (en) | 2002-06-13 | 2006-05-09 | Neuropro Technologies, Inc. | Spinal fusion using an HMG-CoA reductase inhibitor |
US7049348B2 (en) | 2002-07-06 | 2006-05-23 | Kensey Nash Corporation | Resorbable structure for treating and healing of tissue defects |
US20040006146A1 (en) * | 2002-07-06 | 2004-01-08 | Evans Douglas G. | Resorbable structure for treating and healing of tissue defects |
JP3927487B2 (en) | 2002-12-02 | 2007-06-06 | 株式会社大野興業 | Manufacturing method of artificial bone model |
JP2006528515A (en) | 2003-07-24 | 2006-12-21 | テコメット・インコーポレーテッド | Spongy structure |
US8529625B2 (en) * | 2003-08-22 | 2013-09-10 | Smith & Nephew, Inc. | Tissue repair and replacement |
US7723395B2 (en) | 2004-04-29 | 2010-05-25 | Kensey Nash Corporation | Compressed porous materials suitable for implant |
US7189263B2 (en) | 2004-02-03 | 2007-03-13 | Vita Special Purpose Corporation | Biocompatible bone graft material |
US20050208271A1 (en) * | 2004-03-17 | 2005-09-22 | Fasching Rainer J | Bonding method for micro-structured polymers |
US8012501B2 (en) * | 2004-06-10 | 2011-09-06 | Synthes Usa, Llc | Flexible bone composite |
US7250550B2 (en) | 2004-10-22 | 2007-07-31 | Wright Medical Technology, Inc. | Synthetic bone substitute material |
US7323208B2 (en) | 2004-11-30 | 2008-01-29 | The Regents Of The University Of Michigan | Modified porous materials and method of forming the same |
WO2006062518A2 (en) | 2004-12-08 | 2006-06-15 | Interpore Spine Ltd. | Continuous phase composite for musculoskeletal repair |
WO2006116392A2 (en) | 2005-04-27 | 2006-11-02 | The Regents Of The University Of Michigan | Particle-containing complex porous materials |
FI20055304L (en) | 2005-06-13 | 2007-02-20 | Bioretec Oy | A bioabsorbable implant with variable properties |
WO2007016545A2 (en) * | 2005-08-01 | 2007-02-08 | The Regents Of The University Of Michigan | Porous materials having multi-size geometries |
US8029575B2 (en) | 2005-10-25 | 2011-10-04 | Globus Medical, Inc. | Porous and nonporous materials for tissue grafting and repair |
-
2005
- 2005-05-12 WO PCT/US2005/016698 patent/WO2005114322A2/en active Application Filing
- 2005-05-12 US US11/579,783 patent/US7815826B2/en not_active Expired - Fee Related
- 2005-05-12 EP EP05749496A patent/EP1763703A4/en not_active Withdrawn
- 2005-05-12 WO PCT/US2005/016734 patent/WO2005114323A2/en active Application Filing
- 2005-05-12 JP JP2007513374A patent/JP2007537007A/en not_active Withdrawn
- 2005-05-12 US US11/127,298 patent/US20070009606A1/en not_active Abandoned
- 2005-05-12 CA CA002564605A patent/CA2564605A1/en not_active Abandoned
-
2010
- 2010-10-06 US US12/899,033 patent/US20110076762A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of EP1763703A4 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009045176A1 (en) * | 2007-10-03 | 2009-04-09 | Bio-Scaffold International Pte Ltd | Method of making a scaffold for tissue and bone applications |
US11654214B2 (en) | 2013-08-02 | 2023-05-23 | Northwestern University | Ceramic-containing bioactive inks and printing methods for tissue engineering applications |
EP3778790A1 (en) * | 2014-05-15 | 2021-02-17 | Northwestern University | Ink compositions for three-dimensional printing and methods of forming objects using the ink compositions |
US11459473B2 (en) | 2014-05-15 | 2022-10-04 | Northwestern University | Ink compositions for three-dimensional printing and methods of forming objects using the ink compositions |
CN107548349A (en) * | 2015-06-10 | 2018-01-05 | 惠普发展公司有限责任合伙企业 | Build temperature modulation |
Also Published As
Publication number | Publication date |
---|---|
JP2007537007A (en) | 2007-12-20 |
WO2005114322A3 (en) | 2007-03-22 |
EP1763703A2 (en) | 2007-03-21 |
US20080032083A1 (en) | 2008-02-07 |
WO2005114323A2 (en) | 2005-12-01 |
CA2564605A1 (en) | 2005-12-01 |
EP1763703A4 (en) | 2010-12-08 |
WO2005114323A3 (en) | 2006-12-21 |
US20070009606A1 (en) | 2007-01-11 |
US20110076762A1 (en) | 2011-03-31 |
US7815826B2 (en) | 2010-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7815826B2 (en) | Manufacturing process, such as three-dimensional printing, including solvent vapor filming and the like | |
Babaie et al. | Fabrication aspects of porous biomaterials in orthopedic applications: A review | |
Sears et al. | Fabrication of biomimetic bone grafts with multi-material 3D printing | |
JP2010059545A (en) | Mixture for forming porous construct | |
US20110052660A1 (en) | Ceramic scaffolds for bone repair | |
US20200289714A1 (en) | Implantable medical device with thermoplastic composite body and method for forming thermoplastic composite body | |
Jang et al. | Fibrous membrane of nano‐hybrid poly‐L‐lactic acid/silica xerogel for guided bone regeneration | |
Chia et al. | High-resolution direct 3D printed PLGA scaffolds: print and shrink | |
CA2689637A1 (en) | Reticulated particle porous coating for medical implant use | |
JP2017529933A (en) | Hybrid material implant with variable porosity | |
Chen et al. | Lattice microarchitecture for bone tissue engineering from calcium phosphate compared to titanium | |
Monfared et al. | A deep insight into the preparation of ceramic bone scaffolds utilizing robocasting technique | |
Lowmunkong et al. | Transformation of 3DP gypsum model to HA by treating in ammonium phosphate solution | |
JP3451417B2 (en) | Bioceramic-containing cell structure and method for producing the same | |
Cornelsen et al. | Infiltration of 3D printed tricalciumphosphate scaffolds with biodegradable polymers and biomolecules for local drug delivery | |
US20230089343A1 (en) | Implantable medical device with varied composition and porosity, and method for forming same | |
WO2004098456A2 (en) | Porous biostructure partially occupied by interpenetrant and method for making same | |
Cheng et al. | Development of hybrid 3D printing approach for fabrication of high-strength hydroxyapatite bioscaffold using FDM and DLP techniques | |
KR102532543B1 (en) | Absorbing eluting spacer device | |
JP3721343B2 (en) | Cell structure containing bioceramics | |
Copus et al. | Additive Manufacturing Technologies for Bone Tissue Engineering | |
Hofmann et al. | Carvable calcium phosphate bone substitute material | |
Carrillo | 3D-Printing via Binder Jetting and Consolidation of Nano Alumina Bone Scaffold Prototypes | |
Chang et al. | Bone-building scaffolds become smarter | |
JP2023517843A (en) | Bioactive implantable devices and composite biomaterials and methods of making same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2564605 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007513374 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11579783 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005749496 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005749496 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11579783 Country of ref document: US |